Trial intelligence / Profile preview

Adhansia XR (PRC-063) Time Course in Adult ADHD

NCT02225639Phase 3Completed

Sponsor
Rhodes Pharmaceuticals
Start
Aug 2014
Primary completion
Apr 2015
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of methylphenidate osmotic release oral system in attention deficit hyperactivity disorder (ADHD), sponsored by Rhodes Pharmaceuticals. Started Aug 2014; status: completed.

02

Drugs

methylphenidate osmotic release oral system
03

Conditions

attention deficit hyperactivity disorder (ADHD)

Beyond the preview

Go deeper on NCT02225639.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02225639.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call